Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | RBP4 | P02753 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.40 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13419720 | 0.91 | GPR119 (0.58) | GPR119NR1H2PDE4BHDAC1HDAC2 | |
| SCHEMBL30140331 | 0.91 | GPR119 (0.58) | GPR119NR1H2PDE4BHDAC1HDAC2 | |
| SCHEMBL13419722 | 0.89 | PDE4B (0.52) | GPR119NR1H2PDE4BUSP30PDE4D | |
| SCHEMBL5971305 | 0.88 | GPR119 (0.66) | GPR119NR1H2PDE4BPDE4DPDE4A | |
| SCHEMBL12003024 | 0.85 | NR1H2 (0.47) | GPR119NR1H2PDE4BUSP30PDE4D | |
| SCHEMBL22031561 | 0.85 | GPR119 (0.52) | GPR119PDE4BUSP30PDE4DRBP4 | |
| SCHEMBL2581353 | 0.85 | PDE4B (0.53) | NR1H2PDE4BUSP30PDE4DPDE4A | |
| SCHEMBL20425239 | 0.85 | USP30 (0.57) | GPR119PDE4BUSP30PDE4DRBP4 | |
| SCHEMBL4519218 | 0.85 | PDE4B (0.59) | NR1H2PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL22817811 | 0.83 | GPR119 (0.48) | GPR119NR1H2PDE4BUSP30PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186224-B1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | HOFFMANN LA ROCHE (CH) | 2021-04-21 | — | — | EP | disclosed |
| CN-107001259-B | Substituted azetidine derivatives as TAAR ligands | 豪夫迈·罗氏有限公司 | 2019-12-06 | — | — | CN | disclosed |
| US-10023559-B2 | Substituted azetidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3186224-A1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | F. Hoffmann-La Roche AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| US-20170144994-A1 | SUBSTITUTED AZETIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2016030310-A1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-03-03 | — | — | WO | disclosed |
| US-20120302547-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-11-29 | — | — | US | disclosed |
| US-8263772-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2089397-B1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL]-2-PHENYL-5H-THIAZ0L0 [5,4-C]PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-04-09 | — | — | US | disclosed |
| EP-2029609-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007146758-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023559-B2 | Substituted azetidine derivatives | HTR1B, MTNR1B, DRD2 | GPR119 6/4885NR1H2 185/4885PDE4B 612/4885 |
| US-20170144994-A1 | SUBSTITUTED AZETIDINE DERIVATIVES | HTR1B, MTNR1B, DRD2 | GPR119 6/4885NR1H2 185/4885PDE4B 612/4885 |
| US-20120302547-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | GPR119 16/4885NR1H2 241/4885PDE4B 1799/4885 |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | GPR119 16/4885NR1H2 259/4885PDE4B 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.